Clinical Trials Browser

Active not recruiting × lorlatinib × 1 year × Clear all

NCT07556549 2026-05-22

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Active not recruiting

50 enrolled

Thoracic

Non-Small Cell Lung Cancer ALK-positive

NCT05297890 2026-05-19

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

70 enrolled

Thoracic

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Active not recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Active not recruiting

41 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

54 enrolled

Thoracic

Non Small Cell Lung Cancer Metastatic